RT Journal Article
SR Electronic
T1 Efficacy of Probucol on cognitive function in Alzheimer’s disease: Study protocol for a double-blind, placebo-controlled, randomised phase II trial (PIA Study)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.20.21266372
DO 10.1101/2021.11.20.21266372
A1 Virginie Lam
A1 Roger Clarnette
A1 Roslyn Francis
A1 Michael Bynevelt
A1 Gerald F Watts
A1 Leon Flicker
A1 Carolyn Orr
A1 Poh Loh
A1 Nicola T Lautenschlager
A1 Christopher M Reid
A1 Jonathan K Foster
A1 Satvinder Dhaliwal
A1 Suzanne Robinson
A1 Emily Corti
A1 Mauro Vaccarezza
A1 Ben Horgan
A1 Ryusuke Takechi
A1 John C.L Mamo
YR 2021
UL http://medrxiv.org/content/early/2021/11/21/2021.11.20.21266372.abstract
AB Introduction Preclinical, clinical and epidemiological studies support the hypothesis that aberrant systemic metabolism of amyloid-beta (Aβ) in the peripheral circulation is causally related to the development of Alzheimer’s disease (AD). Specifically, recent studies suggest that increased plasma concentrations of lipoprotein-Aβ compromises the brain microvasculature, resulting in extravasation and retention of the lipoprotein-Aβ moiety. The latter results in an inflammatory response and neurodegeneration ensues.Probucol, a historic cholesterol-lowering drug, has been shown in murine models to suppress lipoprotein-Aβ secretion, concomitant with maintaining blood-brain-barrier function and suppressing neurovascular inflammation. Probucol has also been shown to protect cognitive function in dietary-induced amyloidogenic mice.This protocol details the Probucol in Alzheimer’s Study (PIA-study), a double-blind, randomised, placebo-controlled drug intervention trial investigating if Probucol attenuates cognitive decline in patients with mild-to-moderate AD.Objectives The primary objective of the 104-week study is to assess whether Probucol supports cognitive function and delays brain atrophy in AD patients. A secondary objective is to determine whether Probucol treatment will reduce cerebral amyloid burden.Methods & Analysis The study is a phase II single-site, randomised, placebo-controlled, double-blind clinical trial assessing the efficacy of Probucol in AD. A total of 300 participants with mild-to-moderate AD will be recruited and randomised 1:1 (active: placebo). Cognitive function, regional volumetric changes in brain and cerebral amyloid load will be evaluated via the cognitive subscale test, AD assessment scales (ADAS-Cog), magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, respectively, after a 104-week intervention.Ethics & Dissemination The study has been approved by the Bellberry Limited Human Research Ethics Committee (Approval number: HREC2019-11-1063; Version 4, 6th October 2021). The investigator group will disseminate study findings through peer-reviewed publications, key conferences and local stakeholder events.Trial registration This trial has been registered with the Australian New Zealand Clinical Trial Registry (ACTRN12621000726853).Strengths and limitations of this studyThis is the first-in-human (FIH) randomised double-blind placebo-controlled study to assess the efficacy of Probucol in delaying cognitive decline in individuals with mild cognitive impairment (MCI) and mild-to-moderate dementia due to Alzheimer’s disease (AD).The 24-month intervention study will be the first to investigate whether treatment with Probucol will stabilise structural/functional changes in brain and if cerebral amyloid load will decrease in individuals with AD, following treatment with Probucol.Probucol is clinically used to treat cardiovascular disease with well-characterised efficacy and safety profiles, thus reducing risk of the study, and if applicable, accelerate clinical translation of the study findings.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialACTRN12621000726853Funding StatementThe PIA-trial is funded by the National Health and Medical Research Council Medical Research Future Fund for Neurological Disorders (MRF1201204), the Multiple Sclerosis Society of Western Australia (MSWA) and the McCusker Charitable Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approved by BellBerry Human Research Ethics Committee. The approval number is 2019-11-1063I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.